These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15900025)

  • 1. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia--a comment.
    Strupp M; Kalla R; Freilinger T; Dichgans M; Brandt T
    Brain; 2005 Jun; 128(Pt 6):E32; author reply E33. PubMed ID: 15900025
    [No Abstract]   [Full Text] [Related]  

  • 2. Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia.
    Imbrici P; Jaffe SL; Eunson LH; Davies NP; Herd C; Robertson R; Kullmann DM; Hanna MG
    Brain; 2004 Dec; 127(Pt 12):2682-92. PubMed ID: 15483044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of BK channel opener and Kv4 channel inhibitor for treatment of cerebellar ataxia in mutant med mice.
    Abbasi S; Abbasi A; Sarbaz Y
    J Neuropsychiatry Clin Neurosci; 2013; 25(4):E41. PubMed ID: 24247886
    [No Abstract]   [Full Text] [Related]  

  • 4. Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.
    Löhle M; Schrempf W; Wolz M; Reichmann H; Storch A
    Mov Disord; 2008 Jul; 23(9):1314-6. PubMed ID: 18442126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.
    Giordano I; Bogdanow M; Jacobi H; Jahn K; Minnerop M; Schoels L; Synofzik M; Teufel J; Klockgether T
    J Neurol; 2013 Aug; 260(8):2175-6. PubMed ID: 23824358
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
    Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
    Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.
    Schniepp R; Wuehr M; Ackl N; Danek A; Brandt T; Strupp M; Jahn K
    J Neurol; 2011 Sep; 258(9):1708-11. PubMed ID: 21431381
    [No Abstract]   [Full Text] [Related]  

  • 8. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
    Alviña K; Khodakhah K
    J Neurosci; 2010 May; 30(21):7258-68. PubMed ID: 20505092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
    Strupp M; Kalla R; Dichgans M; Freilinger T; Glasauer S; Brandt T
    Neurology; 2004 May; 62(9):1623-5. PubMed ID: 15136697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.
    Claassen J; Teufel J; Kalla R; Spiegel R; Strupp M
    J Neurol; 2013 Feb; 260(2):668-9. PubMed ID: 23183922
    [No Abstract]   [Full Text] [Related]  

  • 11. A CaV2.1 calcium channel mutation rocker reduces the number of postsynaptic AMPA receptors in parallel fiber-Purkinje cell synapses.
    Kodama T; Itsukaichi-Nishida Y; Fukazawa Y; Wakamori M; Miyata M; Molnar E; Mori Y; Shigemoto R; Imoto K
    Eur J Neurosci; 2006 Dec; 24(11):2993-3007. PubMed ID: 17156361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylcholine release at neuromuscular junctions of adult tottering mice is controlled by N-(cav2.2) and R-type (cav2.3) but not L-type (cav1.2) Ca2+ channels.
    Pardo NE; Hajela RK; Atchison WD
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1009-20. PubMed ID: 16982704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
    Feil K; Bremova T; Muth C; Schniepp R; Teufel J; Strupp M
    Cerebellum; 2016 Feb; 15(1):38-42. PubMed ID: 26519380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of calcium channels in the cerebellum of the ataxic and epileptic stargazer mutant mouse.
    Leitch B; Shevtsova O; Guévremont D; Williams J
    Brain Res; 2009 Jul; 1279():156-67. PubMed ID: 19422811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative splicing generates a smaller assortment of CaV2.1 transcripts in cerebellar Purkinje cells than in the cerebellum.
    Kanumilli S; Tringham EW; Payne CE; Dupere JR; Venkateswarlu K; Usowicz MM
    Physiol Genomics; 2006 Jan; 24(2):86-96. PubMed ID: 16278278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.
    Cramer SW; Popa LS; Carter RE; Chen G; Ebner TJ
    J Neurosci; 2015 Apr; 35(14):5664-79. PubMed ID: 25855180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluctuating neuromuscular transmission defects and inverse acetazolamide response in episodic ataxia type 2 associated with the novel CaV2.1 single amino acid substitution R2090Q.
    Melzer N; Classen J; Reiners K; Buttmann M
    J Neurol Sci; 2010 Sep; 296(1-2):104-6. PubMed ID: 20663518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene.
    Tonelli A; D'Angelo MG; Salati R; Villa L; Germinasi C; Frattini T; Meola G; Turconi AC; Bresolin N; Bassi MT
    J Neurol Sci; 2006 Feb; 241(1-2):13-7. PubMed ID: 16325861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.
    Hess E
    Neurology; 2011 Nov; 77(22):1996-7; author reply 1997. PubMed ID: 22123782
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
    Kalla R; Teufel J; Feil K; Muth C; Strupp M
    J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.